Attention Deficit Hyperactivity Disorder (ADHD), Neurofeedback
Conditions
Keywords
NIRS, fNIRS, neurofeedback, attention deficit hyperactivity disorder (ADHD), children
Brief summary
To observe the clinical efficacy and mechanism of functional near-infrared spectroscopy imaging neurofeedback therapy for attention deficit and hyperactivity disorder.
Detailed description
In this study, a parallel controlled study will be conducted to recruit 60 patients with ADHD, 30 patients in the fNIRS group and 30 patients in the drug group. At the same time, 30 healthy controls will be recruited. 6 weeks, 12 sessions of NIRS feedback will be given for participants in NIRS group and healthy controls. 6 weeks of first or second line medication will be given for participants of drug group. Magnetic resonance imaging will be performed at baseline for all participants. SNAP IV, PSQ, CGI will be evaluated at baseline, week 3, week 6 and week 8 for ADHD participants.
Interventions
BEHAVIORALNIRS neurofeedback
Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
DRUGMethylphenidate or Tomoxetine
Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
Sponsors
Xijing Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
Yes
Inclusion criteria
For ADHD patients: Inclusion Criteria: * diagnosed with TD, according to the American Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5); * aged 6-12; * right handed;
Exclusion criteria
* full-scale intelligence quotient below 80(measured by Wechsler Intelligence Scale for Children，WISC) * medical or neurological disorders, psychiatric disorders other than oppositional defiant disorder * current participation in a psychotherapeutic treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in SNAP-IV | Baseline, week 3, week 6, week 8 | Change in SNAP-IV(Swanson, Nolan, and Pelham-IV rating scales) score between groups over time |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in CGI | Baseline, week 3, week 6, week 8 | Change in CGI (Clinical Global Impression Scale) score between groups over time |
| Change in PSQ | Baseline, week 3, week 6, week 8 | Change in PSQ(Parent Symptom Questionnaire) score between groups over time |
| Change in TRS | Baseline, week 3, week 6, week 8 | Change in TRS (Conners' Teacher Rating Scale, TRS )score between groups over time |
Countries
China
Contacts
Primary ContactWenjun Wu, master
Backup ContactHuaning Wang, doctor
Outcome results
None listed